Scotiabank Just Hiked Cameco Price Target to $175 as the Nuclear Renaissance Accelerates

Scotiabank raised Cameco’s price target to $175 from $150 and kept an Outperform rating, with the new target above the $150.40 consensus. The note cites improving fundamentals, tighter uranium supply, and rising nuclear demand tied to AI data centers and Western energy-security priorities. Cameco also reported Q1 2026 adjusted EPS of $0.47 and signed a CAD $2.6 billion uranium supply deal with India spanning 2027-2035.

Analysis

The upgrade matters less as a valuation call on Cameco and more as a signal that the market is beginning to assign strategic scarcity value to the Western nuclear supply chain. If policy support translates into multi-year contracting, the real leverage is not just uranium spot pricing but pricing power across conversion, enrichment, fuel fabrication, and reactor services—areas where supply is tighter and replacement options are slower than miners. That creates a second-order winner set around the ecosystem, while also raising the bar for smaller developers that still need permitting, capex, and financing before they can matter.

The setup is bullish but increasingly front-loaded. CCJ already prices in a good portion of the medium-term narrative, so the next leg likely requires either a meaningful upward reset in long-term uranium contracting or visible acceleration in Westinghouse execution; absent that, the stock can stall even if the structural thesis remains intact. The more interesting near-term catalyst is any incremental evidence that hyperscaler power demand is converting from press-release optionality into actual grid commitments, because that would tighten the timeline for utilities and reactor suppliers faster than for miners.

The main risk is that investors confuse policy intent with deliverability. Nuclear is a long-cycle asset class, and the market tends to over-earn on the first phase of enthusiasm before timelines slip, capex inflates, or project financing bottlenecks emerge. A second-order risk is that a stronger uranium market also incentivizes restarts and new supply from non-core assets, which can cap the upside in the spot tape even while equity multiples stay elevated.

The contrarian view is that the best risk-adjusted expression may not be a fresh outright long in CCJ, but a relative-value basket that captures the secular buildout without paying peak multiple for the best-known name. If the market is correctly anticipating a policy-backed cycle, the beneficiaries with the most torque are likely the less-loved supply-chain participants and equipment/service names, not the incumbent already trading at scarcity valuation.

Key Decisions for Investors

• Trim CCJ into strength and re-enter only on a 10-15% pullback or a reset in uranium spot/term momentum; risk/reward is less attractive here because the stock is already discounting a multi-year build cycle.
• Initiate a basket long of nuclear supply-chain enablers versus CCJ over 3-6 months; the spread trade should outperform if contracting broadens beyond uranium and if reactor/services capex accelerates.
• Buy 6-12 month call spreads on CCJ rather than outright stock to express the structural bull case while capping multiple-compression risk if execution slows or the market pauses.
• Monitor MSFT and AMZN only as indirect confirmations; if either announces additional firm power commitments, add to nuclear beneficiaries on the premise that grid demand is moving from narrative to spend.
• Avoid chasing smaller uranium developers at current levels unless project financing is de-risked; the upside is higher, but the probability-adjusted return is worse if permitting or capex inflation reasserts itself.